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fhis review summarizes publications on non–ST-segment
levation (NSTE) acute coronary syndromes (ACS) be-
ween May 2007 and May 2008 with an emphasis on the
pdated practice guidelines for these conditions published
n North America (1) and Europe (2), as well as novel
ndings from clinical studies. Trial acronyms and abbrevi-
tions are listed in Table 1.
pidemiology and Pathophysiology
ver 1.4 million unique hospitalizations for ACS occur in
he U.S. each year (3), of which approximately 70% are
lassified as either unstable angina or non–ST-segment
levation myocardial infarction (NSTEMI); the remainder
re classified as ST-segment elevation myocardial infarction
STEMI). A global registry showed improvements in ad-
usted 6-month survival between 1999 and 2006 in patients
ith NSTE-ACS (4). Approximately one-half of the re-
uction in deaths in the U.S. population from coronary
eart disease has been attributed to favorable changes in risk
actors, such as the achievement of lower serum cholesterol
5,6) and blood pressure (5,6) and discontinuing smoking
6,7), whereas much of the remainder is attributable to
mproved treatments. In addition, some of the decline in
ase fatality rates may be attributed to more sensitive
etection of myocardial necrosis (and hence identification of
maller NSTEMIs) with the introduction of sensitive car-
iac specific troponin assays (8), the preferred biomarker for
iagnosing myocardial necrosis (9).
Several publications in the past year contributed to our
nderstanding of coronary plaque rupture—the underlying
athophysiology of the majority of ACS events. These were
iscussed in the Year in Atherothrombosis (10). Advances
n our understanding of the biology of coronary plaques will
opefully lead to better identification of vulnerable lesions
nd more effective methods to prevent, diagnose, and treat
oronary artery disease.
rom the TIMI Study Group, Division of Cardiovascular Medicine, Department of
edicine, Brigham and Women’s Hospital, Harvard Medical School, Boston,b
assachusetts.
Manuscript received June 26, 2008; accepted July 1, 2008.007 Practice Guidelines
ithin 2 months, both the American College of Cardiol-
gy/American Heart Association (ACC/AHA) (1) and
uropean Society of Cardiology (ESC) (2) published up-
ated practice guidelines for patients with NSTE-ACS
ncorporating new information available since the 2002
ersions.
CC/AHA 2007 guideline. The most important change
ncludes new Class I recommendations broadening the
election of anticoagulants to include fondaparinux and
ivalirudin in addition to unfractionated heparin (UFH)
nd low-molecular-weight heparin (LMWH) (Table 2).
ore aggressive secondary prevention measures are empha-
ized (low-density lipoprotein cholesterol [LDL-C] target
70 mg/dl, blood pressure 130/80 mm Hg in patients
ith diabetes or chronic kidney disease [CKD]). The
uidelines also explicitly advise against use of therapies that
ow either seem to be harmful (e.g., initiation of hormone
herapy with estrogen plus progestin or estrogen alone,
onsteroidal anti-inflammatory drugs) or of no proven
enefit (e.g., antioxidants, folic acid) in the secondary
revention of coronary events.
SC 2007 guideline. The major new features of the ESC
uideline are similar to the ACC/AHA (fondaparinux,
ivalirudin, more aggressive secondary prevention). More
etailed recommendations for the management of bleeding
omplications, thrombocytopenia, and anemia were added
Table 3).
ifferences between the AHA/ACC and ESC 2007
uidelines. These guidelines are remarkably similar. How-
ver, they differ regarding the recommendations and level of
vidence that support the use of 3 of the 4 anticoagulants
11) (Table 4), and also regarding the loading dose of
lopidogrel. The ACC/AHA update gives a higher Level of
vidence (LOE) to UFH and enoxaparin (Class Ia), but
ower LOE for fondaparinux in conservatively managed
atients (Class Ib). In a nonurgent situation, the ESC
uideline (2) expresses a preference for fondaparinux over
noxaparin (Class Ia). In patients managed with an initial
nvasive approach, the ACC/AHA guideline includes
ondaparinux as 1 of the 4 possible anticoagulants that may
e used (Class Ib), whereas the ESC guidelines do not.
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Year in NSTE-ACS September 23, 2008:1095–103astly, the ESC guidelines declare that a 600-mg clopi-
ogrel loading dose may be used to achieve more rapid
nhibition of platelet function in patients considered for an
nvasive procedure (Class IIa-B), whereas the ACC/AHA
uidelines state that the additive clinical efficacy and safety
f loading doses of clopidogrel 300 mg have not been
igorously established. Given the current equipoise regard-
ng the optimal loading dose of clopidogrel, the results of
he ongoing CURRENT/OASIS-7 trial comparing loading
oses of clopidogrel 300 versus 600 mg in patients with
CS managed with an invasive strategy are eagerly awaited.
isk Stratification
iagnostic tools. Novel observations with both estab-
ished and newer noninvasive diagnostic methods were
hown to be helpful in assessing risk in NSTE-ACS.
ssessment of left ventricular systolic function, even among
atients who are troponin negative, is an important predic-
or of long-term risk (12), and this new finding supports the
pgrading of the recommendation to assess systolic function
rom Class IIa to Class I in the updated ACC/AHA
uidelines (1). Echocardiography can also identify left atrial
ilation (13), functional mitral regurgitation (14), and
iastolic dysfunction (15), each of which has been shown to
e associated with an adverse prognosis. At the other end of
he risk spectrum, a normal computed tomographic angio-
ram (CTA) can expeditiously identify low-risk patients,
hereby reducing unnecessary admissions (Fig. 1) and short-
ning lengths of stay (16). Hence, the updated ACC/AHA
uidelines now consider CTA for selected patients (Class
Ia-B) (1).
isk factors. Diabetes mellitus is independently associated
cronyms
Table 1 Acronyms
ACUITY Acute Catheterization and Urgent Intervention Triage Strategy
CRUSADE Can Rapid Risk Stratification of Unstable Angina Patients
Suppress Adverse Outcomes With Early Implementation of
the ACC/AHA Guidelines
CURRENT Clopidogrel Optimal Loading Dose Usage to Reduce
Recurrent EveNTs
DISPERSE Dose confirmation Study assessing anti-Platelet Effects of
AZD6140 vs. clopidogrel in non–ST-segment Elevation
myocardial infarction
GRACE Global Registry of Acute Coronary Events
ISAR-REACT Intracoronary Stenting and Antithrombotic Regimen—Rapid
Early Action for Coronary Treatment OASISOptimal
Antiplatelet Strategy for InterventionS
OASIS Optimal Antiplatelet Strategy for InterventionS
REPLACE Randomized Evaluation in PCI Linking Angiomax to Reduced
Clinical Events
SYNERGY Superior Yield of the New Strategy of Enoxaparin,
Revascularization, and Glycoprotein IIb/IIIa Inhibitors
TIMI Thrombolysis In Myocardial Infarction
TRITON Trial to Assess Improvement in Therapeutic Outcomes by
Optimizing Platelet Inhibition With Prasugrel
CC/AHA  American College of Cardiology/American Heart Association; PCI  percutaneous
oronary intervention.ith higher mortality in patients with NSTE-ACS (17). che AHA released a scientific statement for hyperglycemia
anagement in patients with ACS (18) that included the
ollowing major recommendations: 1) measure plasma glu-
ose concentrations in all patients with suspected ACS; 2)
onitor glucose closely and consider intensive glucose
ontrol with intravenous insulin in patients with glucose
180 mg/dl in the intensive care unit (ICU); 3) maintain
lucose 180 mg/dl with subcutaneous insulin in the
on-ICU setting; and 4) determine the severity of the
etabolic derangement after discharge in patients with no
rior history of diabetes mellitus who showed hyperglyce-
ia during hospitalization.
Renal dysfunction, a complication also associated with
iabetes and hypertension, was found to be a strong inde-
endent predictor of cardiovascular death in a post-ACS
opulation (19). Lastly the presence of noncoronary vascular
isease, whether manifested as a carotid bruit (20), stroke
21), or peripheral arterial disease (21), was associated with
doubling of mortality at 6 to 12 months. These findings of
ultiple overlapping and inter-related risk factors for ACS
upport a more comprehensive approach to primary and
econdary prevention of coronary heart disease.
iomarkers. Elevated levels of neopterin (a marker of
onocyte activation) 4 months after ACS were found to be
n independent predictor of death and the composite of
eath or major coronary events over a 2-year period (22).
here was a significant lowering of neopterin and attenua-
ion of risk among patients receiving atorvastatin 80 mg
ompared with pravastatin 40 mg, suggesting that high-
ose statin could reduce monocyte activation after ACS,
nd perhaps that this is responsible in part for enhanced
linical benefit. An elevated baseline concentration of my-
loperoxidase, a hemoprotein released during degranulation
f monocytes and neutrophils, was associated with a dou-
ling of nonfatal myocardial infarction (MI) or recurrent
CS in patients presenting with NSTE-ACS after adjust-
ent for multiple clinical and biochemical predictors (23).
hemokines ligand-5 and -18 (mediators of monocyte
ecruitment induced by ischemia) were transiently elevated
n unstable angina and were associated with refractory
ymptoms, adding further to the data supporting a critical
ole for monocytes in NSTE-ACS (24). Elevated circulat-
ng levels of osteoprotegerin (a modulator of immune
unction and inflammation) were strongly associated with
ong-term mortality and hospitalization for heart failure
cross the spectrum of ACS (25). Concentrations of angio-
enin (26) (a mitogen of endothelial cells and activator of
atrix metalloproteinases and plasminogen-activated plas-
in pathways) and circulating endothelial cells (27) were
ound to be elevated in ACS patients and to be associated
ith increased risk. Research on myeloid-related protein
/14 suggests that this marker may permit detection of
nstable plaques (28), and that it is an independent predic-
or of long-term risk of death or MI (29). The findings
ummarized above underscore the important role of leuko-
ytes and inflammation in the pathogenesis of ACS.
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September 23, 2008:1095–103 Year in NSTE-ACSNovel observations with platelet and genetic markers
ere also described during the past year. Plasma concentra-
ions of SCUBE1 (a novel platelet protein) were at or below
he minimum detectable level in healthy subjects and
atients with stable coronary artery disease, but increased
ore than 4-fold as early as 6 h after the onset of symptoms
f ACS, a finding consistent with its proposed role as a
arker of platelet activation (30). Important new findings
ith genetic markers in patients after an ACS event
nclude the association of a polymorphism of the kinesin-
ike protein 6 gene (which regulates intracellular trans-
ort of protein complexes, membrane organelles, and
essenger ribonucleic acid along microtubules) with
igher event rates but better response to high-dose statins,
ajor Changes in the 2007 ACC/AHA UA/NSTEMI Guideline
Table 2 Major Changes in the 2007 ACC/AHA UA/NSTEMI Gu
Pre-hospital management/emergency department
Utilize 9-1-1 or ambulance (I-B), advise aspirin (IIa-B), nitroglycerin (IIa-C), perform
Coronary computed tomographic angiography in selected, lower-risk patients (IIa-
Anti-ischemic/analgesics
Avoid intravenous nitrates (III-C), ACE-I (III-B), beta-blockers (III-A) in patients with
ARBs may be substituted for ACE-I (I-A)
Avoid NSAIDs (other than aspirin) during hospitalization (III-C)
Antiplatelet therapy
Drugs to minimize the risk of recurrent GI bleeding should be prescribed (I-B) in th
May omit GPI in an invasive approach with bivalirudin and clopidogrel 6 h befor
Anticoagulant therapy
Invasive strategy: fondaparinux or bivalirudin may be used as alternatives to UFH,
Conservative strategy: fondaparinux is acceptable (I-B), and preferred if an increas
Additional considerations for antithrombotic agents
Conservative strategy (low risk): discontinue GPI (immediately), UFH (by 48 h), eno
CABG: Discontinue clopidogrel (5 to 7 days), short-acting GPIs (4 h), enoxaparin (1
Urgent CABG: experienced surgeons may operate 5 days of clopidogrel if the inc
Initial management strategy
Initial invasive strategy is favored if high-risk scores (I-A) or chronic kidney disease
Noninvasive assessment of left ventricular function is recommended in patients m
Revascularization
PCI should not be performed in stable patients with persistently occluded infarct-r
PCI of left main stenosis 50% may be performed in patients not eligible for CAB
Long-term medical therapy
Lower-dose aspirin (75 to 162 mg) if no stenting (I-A), increased bleeding risk (IIa
[I-B], paclitaxel-DES 6 months [I-B])
Extended duration of clopidogrel to ideally 1 year after BMS and minimum of 12 m
Aldosterone antagonists in addition to ACE-I in patients with LVEF 0.40 and eith
Secondary prevention
Fasting lipids should be assessed within 24 h of hospitalization (I-C)
Lipid-lowering: initiate before discharge, target LDL-C 100 mg/dl (I-A), optional t
Target blood pressure in patients with diabetes or chronic kidney disease was low
Annual influenza vaccine for all patients (I-B)
Screen for and refer/treat for depression (IIa-B)
Do not initiate hormone therapy with estrogen plus progestin or estrogen alone in pos
Do not use antioxidant vitamins or folic acid (with or without vitamins B6 and B12
he numeral designates the class recommendation grade, and the capital letter designates the leve
rom Anderson et al. (1).
ACC  American College of Cardiology; ACE-I  angiotensin-converting enzyme inhibitor; ACS 
MS  bare metal stent; CABG  coronary artery bypass graft surgery; DES  drug eluting stent; E
ipoprotein cholesterol; LVEF  left ventricular ejection fraction; NSAID  nonsteroidal anti-infla
nfarction; PCI  percutaneous coronary intervention; UA  unstable angina; UFH  unfractionatendependent of the effects on lipid and C-reactive protein levels pCRP) (31). A second polymorphism (GJA4) that affects
acrophage adhesion was associated with increased mortality
fter ACS (32).
With a growing number of biomarkers associated with
dverse clinical outcomes, an important challenge facing
nvestigators is the identification of a parsimonious menu of
iomarkers that can be integrated with imaging (33) and
ther diagnostic modalities to improve the prediction of
eath and cardiovascular complications in a cost-effective
anner (34).
ntiplatelet Agents
esearch during the past year has focused on variable
e
valuate 12-lead ECGs (IIa-B)
ynamic instability
ith a prior history of GI bleeding
IIa-B)
parin (I-B)
eding risk (I-B)
in/fondaparinux (by discharge or day 8) (I-A)
4 h), fondaparinux (24 h), bivalirudin (3 h) before CABG (I-B)
tal bleeding risk is acceptable (I-C)
) are present
d conservatively (I-B)
arteries after NSTEMI (III-B)
B)
d after an initial period after stenting (BMS 1 month [I-A], sirolimus-DES 3 months
s after DES (I-B)
rt failure or diabetes (I-A)
DL-C 70 mg/dl (IIa-A)
130/80 mm Hg (I-A)
pausal women after NSTE-ACS for secondary prevention of coronary events (III-A)
econdary prevention (III-A)
dence (e.g., IIa-B class grade IIa recommendation with Level of Evidence: B). Data were adapted
coronary syndromes; AHA  American Heart Association; ARB  angiotensin receptor blocker;
lectrocardiogram; GI  gastrointestinal; GPI  glycoprotein IIb/IIIa inhibitor; LDL-C  low-density
ry drug; NSTE  non–ST-segment elevation; NSTEMI  non–ST-segment elevation myocardial
rin.idelin
and e
B)
hemod
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Year in NSTE-ACS September 23, 2008:1095–103herapies that deliver a greater degree of platelet inhibition
ore quickly, and improving safety.
Concomitant therapies (e.g., omeprazole [35]) and ge-
etic polymorphisms of the cytochrome P450 isoforms (36),
n addition to differences in patient clinical characteristics,
ay affect the degree of platelet inhibition achieved with
lopidogrel, either by interfering with drug absorption or
lowing metabolism of the prodrug to the active form. One
imple and effective approach to reduce the number of
yporesponders is to administer a larger loading dose (i.e.,
600 mg) to all patients, including a reload of 600 mg in
atients who were previously receiving the standard 75-mg
aily maintenance dose of clopidogrel (37). However, an
ven more promising strategy seems to be the incorporation
f a measurement of platelet inhibition after clopidogrel
oading using vasodilator-stimulated phosphoprotein phos-
horylation (VASP) index, followed by dose titration to a
arget level of antiplatelet activity. Such an approach was
hown to reduce major adverse cardiovascular events com-
ared with simply administering a 600-mg loading dose
nique Recommendationsn the ESC NSTE-ACS Guideline
Table 3 Unique Recommendationsin the ESC NSTE-ACS Guideline
1. Bleeding complications
Consider the patient’s bleeding risk when selecting the antithrombotic agents,
dose, duration, and type of vascular access (I-B)
Interrupt/neutralize antithrombotic therapies to control major bleeding (I-C)
Continue antithrombotic treatments in the setting of minor bleeding (I-C)
Withhold transfusions in hemodynamically stable patients with hematocrit
25% (I-C)
2. Thrombocytopenia
Interrupt suspected therapies if the platelet count is 100,000/l (I-C)
Platelet counts 10,000/l induced by glycoprotein IIb/IIIa inhibitors requires
platelet transfusions with or without fibrinogen supplementation with fresh
frozen plasma or cryoprecipitate in the case of bleeding (I-C)
Substitute a direct thrombin inhibitor for heparin in the case of HIT (I-C)
Recognize that HIT can be prevented by using fondaparinux or bivalirudin (I-B)
3. Anemia
Consider baseline hemoglobin in the assessment of initial risk since it is an
independent marker of ischemia and bleeding (I-B)
Avoid worsening of anemia by bleeding using all necessary measures (I-B)
Consider transfusions only in the case of compromised hemodynamic status (I-C)
he numeral designates the class recommendation grade, and the capital letter designates the
evel of evidence (e.g., IIa-B  grade IIa class recommendation with Level of Evidence: B).
ESC  European Society of Cardiology; HIT  heparin-induced thrombocytopenia; other abbre-
iations as in Table 2.
uideline Recommendations for Anticoagulants
Table 4 Guideline Recommendations for Anticoagulants
Early Conservative Early Invasive
ACC/AHA ESC ACC/AHA ESC
Unfractionated heparin I-A I-C I-A I-C
Enoxaparin I-A IIa-B I-A IIa-B
Fondaparinux I-B I-A I-B —
Bivalirudin — — I-B I-B
he numeral designates the class recommendation grade, and the capital letter designates the
evel of evidence (e.g., IIa-B  grade IIa class recommendation with Level of Evidence: B). Data
ere adapted from Anderson et al. (1) and Eikelboom et al. (11).
ACC/AHA  American College of Cardiology/American Heart Association; ESC  European
ociety of Cardiology.ithout assessment of VASP in all patients undergoing
ercutaneous coronary intervention (PCI), many of whom
resented with NSTE-ACS (38). However, VASP assays
ust be run in specialized coagulation laboratories and
herefore are not widely available. Thus, confirmation of
imilar results using a point-of-care device (39) represents
n important goal of ongoing research.
Longer duration of clopidogrel therapy without interrup-
ion seems to be important for reducing mortality and
ortality after ACS. Rates of death and acute myocardial
nfarction (AMI) were increased, both in patients treated
edically and after stenting, during the first 6 months after
essation of clopidogrel (40) (Fig. 2).
Newer, more potent, faster-acting oral antiplatelet ther-
pies are on the horizon. Prasugrel, a novel thienopyridine
hat achieves greater platelet inhibition than clopidogrel
41), significantly reduced the composite of cardiovascular
Figure 1 Use of MDCT May Reduce Unnecessary Admissions
Slightly fewer patients were admitted in the multidetector computed tomogra-
phy (MDCT)-based strategy (67 vs. 55). Unnecessary admissions were reduced
with utilization of an MDCT-based strategy (blue bars) to less than one-third of
the total observed with the conventional diagnostic strategy (yellow bars).
ACS  acute coronary syndromes. Reprinted with permission from
Chang et al. (16).
Figure 2 Incidence of Death or AMI After
Stopping Treatment With Clopidogrel
Green bars  medically treated patients; purple bars  PCI-treated patients.
AMI  acute myocardial infarction; PCI  percutaneous coronary intervention.
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September 23, 2008:1095–103 Year in NSTE-ACSeath, nonfatal MI, or nonfatal stroke by 19% through 15
onths in 13,608 patients with moderate- to high-risk
CS scheduled to undergo PCI in the TRITON–TIMI 38
rial (42). In addition, prasugrel significantly reduced myo-
ardial infarction by 24%, the need for urgent revascular-
zation by 34%, and stent thrombosis by 52% (43) (Fig. 3).
he benefits of prasugrel were seen during both the first 3
ays as well as during later follow-up (44). However, these
eductions in ischemic complications were achieved at a cost
f significant increases in bleeding (hazard ratio 1.32),
ncluding absolute excesses of 0.5% and 0.3% in the rates of
ife-threatening and fatal bleeding, respectively (42).
AZD6140 is a potent oral P2Y12 receptor antagonist that
iffers from clopidogrel and prasugrel in that its effects are
eversible (45). In the DISPERSE-2 trial, this agent
howed a favorable trend in reducing MI compared with
lopidogrel, a similar rate of major bleeding, but an increase
n minor bleeding (46).
The oral protease-activated receptor (PAR)-1 antagonist
CH 53048 was studied in 1,030 patients undergoing
onurgent PCI or coronary angiography with planned PCI
n a phase II placebo-controlled, dose-ranging trial (47).
he drug achieved 80% inhibition of thrombin receptor
gonist peptide-induced platelet aggregation rapidly, with
o increase in Thrombolysis In Myocardial Infarction
leeding. Two large outcome trials with this PAR-1 antag-
nist are now underway.
nticoagulant Agents
he long-term results of the ACUITY trial, a 3-arm,
pen-label trial comparing UFH or enoxaparin  a glyco-
rotein IIb/IIIa inhibitor (GPI) versus bivalirudin  GPI
ersus bivalirudin monotherapy in patients with NSTE-
CS undergoing early invasive management, revealed sim-
lar rates of the net outcome of death, MI, unplanned
evascularization for ischemia, or non–coronary artery by-
Figure 3 Stent Thrombosis at 1 Year
With Prasugrel Versus Clopidogrel
Rates of Academic Research consortium definite or probable stent thrombosis
at 1 year in the TRITON–TIMI 38 trial. Blue bars  clopidogrel; red bars 
prasugrel. Adapted from Wiviott et al. (43).mass graft major bleeding (15.4%, 16.0%, and 16.2%, re-
pectively) and mortality alone (3.9%, 3.9%, and 3.8%,
espectively) across the 3 groups at 1 year. A strategy of
witching to bivalirudin monotherapy, either before (48) or
t the time of PCI (49), was shown to be safer and as
ffective as UFH or enoxaparin  GPI regardless of
hether preceding anticoagulation had been initiated before
andomization or not.
However, as reported in the preliminary results from the
SAR-REACT 3 trial (50), bivalirudin (0.75 mg/kg fol-
owed by 1.75 mg/kg/h infusion) was not superior to the
uch simpler and less expensive strategy of UFH mono-
herapy (140 U/kg bolus with no infusion) in reducing the
et composite outcome (risk ratio [RR]: 0.94, p  NS) in
,570 biomarker-negative patients with stable or unstable
ngina who had received 600 mg clopidogrel 2 h before
cheduled PCI. The incidence of major bleeding was
ignificantly reduced by 33% with bivalirudin, with no
tatistical difference in the composite of death, MI, or
rgent revascularization. These findings add to the growing
umber of studies that have shown less bleeding and similar
ates of ischemic complications with bivalirudin compared
ith other antithrombotic regimens.
Subgroup analyses from the OASIS-5 trial comparing
ondaparinux with enoxaparin in NSTE-ACS yielded im-
ortant information in 2 high-risk subgroups: patients
ndergoing PCI and those with renal insufficiency. Among
,238 patients undergoing PCI, fondaparinux was associ-
ted with similar rates of ischemic complications at day 9
6.3% vs. 6.2%), significantly reduced major bleeding by
4%, but a 2-fold excess in catheter thrombosis (0.9% vs.
.4%) (51). An analysis of outcomes stratified by renal
unction revealed greater differences in bleeding between
ondaparinux and enoxaparin as renal function declined,
articularly in patients with a calculated glomerular filtra-
ion rate 58 ml/min/1.73 m2 (52). Like bivalirudin,
ondaparinux also seems to be associated with less bleeding
han heparin or enoxaparin, and fondaparinux is recom-
ended in patients managed with an initial conservative
pproach who are at high risk of bleeding (ACC/AHA
lass Ib, ESC Class Ia) (1,2).
Several new anticoagulants are under development, with a
articular interest in short-acting, reversible agents and oral
nticoagulants that inhibit factors Xa or IIa (53). Two
hort-acting, reversible drugs that reported phase I results in
he past year included an antidote-controlled modulator of
actor IXa activity (54) and an anti–von Willebrand factor
ptamer (55). Both are intended for clinical use in ACS and
CI with the hope that their rapid reversibility will reduce
leeding compared with existing anticoagulants.
leeding Complications
f Antithrombotic Therapy
esearch exploring the relationship between bleeding and
ortality, strategies to reduce bleeding, and the clinical
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Year in NSTE-ACS September 23, 2008:1095–103onundrums that physicians face in combining multiple
ntithrombotic agents (1,2,56) were important topics re-
orted in the past year and represent major additions to
oth NSTE-ACS practice guidelines.
New analyses from REPLACE-2 (57) (a trial of 6,010
atients undergoing elective or urgent PCI comparing 2
ntithrombotic regimens) and 4 studies with abciximab (58)
howed that major bleeding was independently associated
ith mortality in patients undergoing PCI. However, es-
ablishing a causal relationship between bleeding and isch-
mic complications including death remains elusive because
f the number and complex interactions of the other clinical
haracteristics and events (e.g., thrombocytopenia [59],
ransfusions [60]) that tend to occur in such patients.
ndeed, one comprehensive analysis of 40,087 patients with
MI in the GRACE registry concluded that although
leeding may have been associated with adverse outcomes in
ome patients, it was more often simply an indicator of
atients at higher risk for adverse outcomes (61).
Efforts to reduce bleeding include the use of: 1) weight-
djusted (as opposed to fixed) doses of anticoagulants (62);
) modified dosing in patients with renal dysfunction (63)
nd when concomitant GP IIb/IIIa inhibitors are adminis-
ered (64); and 3) the selection of fondaparinux (conserva-
ive strategy) or bivalirudin without GPI (invasive strategy)
n patients who are at higher risk of bleeding (1,2).
Because dual antiplatelet therapy with aspirin and clopi-
ogrel is a Class Ia indication in patients with NSTE-ACS
1,2) and the recommended treatment duration has been
xtended to 1 year in patients with drug-eluting stents (65)
nd post–NSTE-ACS (1,2), long-term data regarding the
afety of dual antiplatelet therapy in patients also receiving
arfarin has become increasingly important. Data from
Figure 4 Death, MI, or Rehospitalization in NSTE-ACS Trials of an
Odds ratio with 95% confidence intervals are plotted for all patients, women, and
ACS  acute coronary syndrome; MI  myocardial infarction; NSTE  non–ST-segoth the GRACE (66) and CRUSADE (67) registries 0eported that most patients on prior warfarin who receive
tents are discharged on all 3 agents. Adjusted analyses
omparing single versus dual antiplatelet therapy among
atients who are also discharged on warfarin show no major
ifferences in outcomes. However, the numbers of patients
n these retrospective registry analyses are modest and
andomized data are lacking.
nvasive Versus
onservative Management Strategies
ew analyses of key patient subgroups showed a benefit of
n early invasive strategy among women, the elderly, and
atients with CKD, groups that historically have been less
ikely to undergo angiography. In a meta-analysis of data
rom 8 trials involving 3,075 women and 7,075 men, an
arly invasive strategy reduced the composite of death, MI,
r recurrent ACS by 19% in women and 27% in men
Fig. 4) (68). Among women who had a positive biomarker
t baseline, an invasive strategy reduced the odds of an event
y 33%, whereas in biomarker-negative women there was
nly a 6% reduction (interaction p  0.08). In 1,936 elderly
age 75 years) patients with NSTEMI enrolled in a
erman ACS registry, an invasive strategy significantly
educed in-hospital mortality by 45% and the composite of
eath and nonfatal MI by 49% with a trend toward more
leeding (8.8% vs. 5.8%), adjusted for confounding using a
ropensity score analysis (69). Pooling data from 5 trials
hat enrolled 1,453 patients with NSTE-ACS and moder-
te to severe CKD (stage 3 to 5), an early invasive strategy
ignificantly reduced rehospitalizations by 24% and tended
o have favorable effects on all-cause mortality (RR:
sive Versus Conservative Treatment Strategy
levation.Inva
men.
ment e.76), nonfatal MI (RR: 0.78), and the composite of death
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une 2008).
In parallel with these analyses showing benefit with an
arly invasive strategy in high-risk groups, an analysis of the
emporal trend of the use of PCI, coronary artery bypass
raft, and medical management of NSTE-ACS patients in
he CRUSADE registry (70) showed a significant increase
n the use of PCI from 38% to 53% between January 2002
nd June 2005. Furthermore, analyses from the SYNERGY
linical trial showed significantly lower rates of death or MI
s the time interval from presentation to angiography
ecreased, with an adjusted odds ratio of 0.56 for angiog-
aphy performed6 h compared with patients who received
ngiography at any later time or who never received angiog-
aphy (71). The benefit of an early invasive approach,
ompared with angiography deferred until later, persisted
ntil angiography was performed at up to 30 h. Finally, data
rom a Canadian ACS registry identified that the major
eason that patients were not referred for angiography was
he physician impression that the patients were “not at high
nough risk,” although 59% were at intermediate to high
isk according to the Thrombolysis In Myocardial Infarc-
ion risk score (72). With greater implementation of risk
tratification as endorsed in the updated guidelines (1,2) and
ew information regarding the benefit of an early invasive
trategy in subgroups with prior low rates of utilization (e.g.,
omen and patients with CKD), the current trends of more
requent and earlier use of angiography are expected to
ontinue.
valuation of Quality of Care
number of publications evaluated the quality of care in
elected patient subgroups and health care settings. Sequen-
ial Canadian ACS registries documented an increase from
9% to 51% in the use of optimal evidence-based pharma-
ologic therapies from 1999 to 2001 compared with 2002 to
003 (73), and use of these optimal therapies was associated
ith significantly lower adjusted 1-year mortality (odds
atio: 0.54). However, older (74,75), higher-risk (76) pa-
ients and those without cardiology follow-up (77) are less
ikely to receive recommended therapies. From a hospital
erspective, the most effective method for improving the
uality of care seems to be implementation of quality
mprovement tools, such as those used in the CRUSADE
nitiative (78).
With 2008 being an election year in the U.S., we end this
eview with a proposed solution to the important problem of
oncompliance with secondary preventive therapies in pa-
ients with ACS. One major barrier to the use of effective
econdary prevention is the high out-of-pocket total cost of
hese therapies. A cost-effectiveness model that compared
urrent U.S. prescription drug coverage with full coverage of
roven medical therapies after MI showed greater func-
ional life expectancy (0.35 quality-adjusted life years) and a
2,500 reduction in resource use from a societal perspective
1ith a full-coverage program (79). However, from the
erspective of Medicare, such a change in coverage would
esult in an increased cost of $7,182 per quality-adjusted life
ear (well below the generally accepted threshold of $60,000
er quality-adjusted life year for a cost-effective interven-
ion), but additional funding would be required to realize
his benefit.
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